Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma
- PMID: 34053904
- DOI: 10.1016/j.euf.2021.05.002
Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma
Abstract
Background: Among various clinicopathologic factors used to identify low-risk upper tract urothelial carcinoma (UTUC), tumor grade and stage are of utmost importance. The clinical value added by inclusion of other risk factors remains unproven.
Objective: To assess the performance of a tumor grade- and stage-based (GS) model to identify patients with UTUC for whom kidney-sparing surgery (KSS) could be attempted.
Design, setting, and participants: In this international study, we reviewed the medical records of 1240 patients with UTUC who underwent radical nephroureterectomy. Complete data needed for risk stratification according to the European Association of Urology (EAU) and National Comprehensive Cancer Network (NCCN) guidelines were available for 560 patients.
Outcome measurements and statistical analysis: Univariable and multivariable logistic regression analyses were performed to determine if risk factors were associated with the presence of localized UTUC. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the GS, EAU, and NCCN models in predicting pathologic stage were calculated.
Results and limitations: Overall, 198 patients (35%) had clinically low-grade, noninvasive tumors, and 283 (51%) had ≤pT1disease. On multivariable analyses, none of the EAU and NCCN risk factors were associated with the presence of non-muscle-invasive UTUC among patients with low-grade and low-stage UTUC. The GS model exhibited the highest accuracy, sensitivity, and negative predictive value among all three models. According to the GS, EAU, and NCCN models, the proportion of patients eligible for KSS was 35%, 6%, and 4%, respectively. Decision curve analysis revealed that the net benefit of the three models was similar within the clinically reasonable range of probability thresholds.
Conclusions: The GS model showed favorable predictive accuracy and identified a greater number of KSS-eligible patients than the EAU and NCCN models. A decision-making algorithm that weighs the benefits of avoiding unnecessary kidney loss against the risk of undertreatment in case of advanced carcinoma is necessary for individualized treatment for UTUC patients.
Patient summary: We assessed the ability of three models to predict low-grade, low-stage disease in patients with cancer of the upper urinary tract. No risk factors other than grade assessed on biopsy and stage assessed from scans were associated with better prediction of localized cancer. A model based on grade and stage may help to identify patients who could benefit from kidney-sparing treatment of their cancer.
Keywords: Conservative treatment; Kidney-sparing surgery; Low-grade tumor; Predictive model; Upper tract urothelial carcinoma.
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.
Similar articles
-
A pretreatment nomogram to predict muscle-invasiveness in high-risk upper tract urothelial carcinoma (ROBUUST 2.0 collaborative group).Minerva Urol Nephrol. 2025 Feb;77(1):57-68. doi: 10.23736/S2724-6051.25.05934-8. Minerva Urol Nephrol. 2025. PMID: 40183183
-
Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.Eur Urol. 2021 Oct;80(4):507-515. doi: 10.1016/j.eururo.2021.05.004. Epub 2021 May 20. Eur Urol. 2021. PMID: 34023164
-
Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study.Eur Urol Focus. 2022 Mar;8(2):491-497. doi: 10.1016/j.euf.2021.03.018. Epub 2021 Mar 26. Eur Urol Focus. 2022. PMID: 33773965
-
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update.Eur Urol. 2018 Jan;73(1):111-122. doi: 10.1016/j.eururo.2017.07.036. Epub 2017 Sep 1. Eur Urol. 2018. PMID: 28867446 Review.
-
Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease.Eur Urol Focus. 2023 Sep;9(5):807-812. doi: 10.1016/j.euf.2023.03.016. Epub 2023 Apr 12. Eur Urol Focus. 2023. PMID: 37059620 Review.
Cited by
-
A nomogram for overall survival of second primary cancers following upper-tract urothelial carcinoma: a SEER population-based study.Transl Cancer Res. 2024 Aug 31;13(8):4131-4145. doi: 10.21037/tcr-24-515. Epub 2024 Aug 12. Transl Cancer Res. 2024. PMID: 39262482 Free PMC article.
-
Diagnosis, workup, and risk stratification of upper tract urothelial carcinoma.Transl Androl Urol. 2023 Sep 30;12(9):1456-1468. doi: 10.21037/tau-23-45. Epub 2023 Aug 4. Transl Androl Urol. 2023. PMID: 37814699 Free PMC article. Review.
-
Development and Validation of a Preoperative Nomogram for Endoscopic Management Decision Making in Upper Urinary Tract Urothelial Carcinoma.Ann Surg Oncol. 2024 Feb;31(2):1393-1401. doi: 10.1245/s10434-023-14514-z. Epub 2023 Nov 5. Ann Surg Oncol. 2024. PMID: 37925655
-
Development and validation of a prediction model for early recurrence in upper tract urothelial carcinoma treated with radical nephroureterectomy.BMC Cancer. 2025 Apr 30;25(1):808. doi: 10.1186/s12885-025-14180-2. BMC Cancer. 2025. PMID: 40307701 Free PMC article.
-
Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee.Cancers (Basel). 2022 Nov 6;14(21):5452. doi: 10.3390/cancers14215452. Cancers (Basel). 2022. PMID: 36358870 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical